

CONTENTS

1. INTRODUCTION

* Objective of the investigation	1
1.1 Improved drug delivery systems – A perspective	1
1.2 Overview of ocular anatomy and physiology relevant to ophthalmic drug delivery	6
1.3 Factors affecting bioavailability of topically applied drugs	11
1.4 Ophthalmic drug delivery systems	15
1.4.1 Conventional systems in ophthalmic drug delivery .	16
1.4.2 Improved/Novel ophthalmic drug delivery systems	18
1.5 Important factors to be considered in the development of ophthalmic dosage forms	30
1.6. In-vivo considerations	37
1.7. Ocular inflammation	39
1.8. Drug profile	43

2. MATERIALS, EXPERIMENTAL, RESULTS & DISCUSSION

2.1 Experimental Design	50
2.2 Materials	55
2.3 Preformulation studies	59
2.3.1 Standardization of drugs and additives	59
2.3.2 Development of analytical methods	68
2.3.3 Cleaning and sterilization of closures and containers	82
2.3.4 Stability and sterilization of ketorolac tromethamine aqueous solution.....	85
2.3.5 Compatibility studies	90
2.3.6 Sterilization of ketorolac tromethamine powder....	107

2.4 Prototype formulation	111
2.4.1 Ketorolac tromethamine (0.5% w/v) ophthalmic solutions	111
2.4.2 Ketorolac tromethamine (0.5% w/w) viscous solutions	115
2.4.3 Ophthalmic carbopol gel of ketorolac tromethamine	117
2.4.4 Ophthalmic poloxamer gels of ketorolac tromethamine	119
2.4.5 Ketorolac tromethamine (0.5% w/w) ointment	123
2.5 Preparation of selected KT ophthalmic formulations ...	127
2.5.1 KT (0.5% w/v) conventional ophthalmic solutions	127
2.5.2 KT (0.5% w/w) ophthalmic viscous solutions	129
2.5.3 Long acting KT ophthalmic carbopol gel	131
2.5.4 Thermoreversible ophthalmic gel of KT	132
2.5.5 KT (0.5% w/w) ophthalmic ointment	134
2.6 Evaluation of the prepared formulations	136
2.6.1 Physicochemical characterization	136
2.6.2 Accelerated stability studies	148
2.6.3 Microbiological evaluation of the formulations ...	166
2.6.4 Biological evaluation	173
2.6.4.1 The eye-irritation test	173
2.6.4.2 Efficacy study: Anti-inflammatory activity of ketorolac tromethamine conventional ophthalmic solution (FFS-1)	176
2.6.4.3 Determination of the aqueous humor drug concentration time profile	188
3. SUMMARY AND CONCLUSION	204
4. REFERENCES	210